Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2012

View Archived Issues

Plant-based platform developed for production of antimalarial drug

Takeda identifies benzazepine derivatives for treatment of obesity

Selective GlyT2 inhibitor shows promising analgesic effects in vivo

Mochida reports potent in vivo analgesic activity for proprietary drug

European team generates water-stable, helicate-like products as potential antimicrobials

Oleanolic acid derivative shows promise in model of MS

New panthetheinase inhibitors presented to treat malaria

Exonhit discloses novel tubulin polymerization inhibitors

Boehringer Ingelheim synthesizes novel chemokine CCR2 receptor antagonists

GlaxoSmithKline enrolling toddlers in phase I pneumococcal vaccine trial

Recruitment begins in phase III BEACON study

New phosphodiesterase inhibitors prepared at IntraCellular Therapies

Cardiolynx patents new pioglitazone derivatives

Novel peptide conjugates for bacterial infections designed in Canada

Lundbeck launches antiepileptic tablet in U.S.

Resubmitted pixantrone NDA to be reviewed by FDA's ODAC

New alpha-glucosidase inhibitors developed in Spain

Phase IIb trial of photodynamic therapy for cervical intraepithelial neoplasia advances

Phylogica enters new collaboration involving Phylomer peptide platform

Enrollment in phase II KRN-321 study begins in Japan

Agile Therapeutics completes phase III program for contraceptive patch

Advaxis to raise additional funding with sale of convertible promissory notes

Tivozanib superior to sorafenib in phase III study

Alnylam reports encouraging preclinical data on RNAi therapeutic for Huntington's disease

Glenmark begins pivotal study of antidiarrheal drug in India

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
ATNM-400 radioconjugate shows efficacy in resistant breast cancer
BioWorld Science
Although hormone receptor-positive (HR+) breast cancer accounts for over 70% of cases, 20%-30% of patients still experience relapse despite endocrine therapies...